All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – In a deal that adds another clinical-stage program to its pipeline, U.S.-China biotech Oncologie Inc. has picked up global rights to phase II-ready anti-DLL4/VEGF bispecific antibody navicixizumab from London-based Mereo Biopharma Group plc.